InflaRx N.V. (IFRX): Price and Financial Metrics

InflaRx N.V. (IFRX): $1.40

0.00 (0.00%)

POWR Rating

Component Grades








Add IFRX to Watchlist
Sign Up

Industry: Biotech




#45 of 339

in industry

IFRX Price/Volume Stats

Current price $1.40 52-week high $7.25
Prev. close $1.40 52-week low $1.14
Day low $1.40 Volume 1,050
Day high $1.40 Avg. volume 851,958
50-day MA $2.07 Dividend yield N/A
200-day MA $3.30 Market Cap 62.59M

IFRX Stock Price Chart Interactive Chart >

InflaRx N.V. (IFRX) Company Bio

Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.

IFRX Latest News Stream

Event/Time News Detail
Loading, please wait...

IFRX Latest Social Stream

Loading social stream, please wait...

View Full IFRX Social Stream

Latest IFRX News From Around the Web

Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.

InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 6, 2023

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its P

Yahoo | November 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today!

William White on InvestorPlace | November 3, 2023

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoingSix clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG)FDA regulatory pathway towards BLA in broader acute respiratory distress syndrome (ARDS) indication discussed in encouraging FDA Type C meetingMAA for vilobelimab for treatment of SARS-CoV-2 induced septic ARDS in critically i

Yahoo | November 1, 2023

12 Best German Stocks To Buy Now

In this piece, we will take a look at the 12 best German stocks to buy now. If you want to skip our overview of the German economy and how it has struggled as of late, then check out 5 Best German Stocks To Buy Now. The outbreak of the Russian invasion of Ukraine upended […]

Yahoo | October 31, 2023

Read More 'IFRX' Stories Here

IFRX Price Returns

1-mo -18.60%
3-mo -65.94%
6-mo -67.52%
1-year -45.74%
3-year -64.82%
5-year -95.38%
YTD -54.84%
2022 -34.87%
2021 -5.37%
2020 27.02%
2019 -89.11%
2018 73.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!